Pharma Focus Asia
KP - Sustainable Packaging Solutions

WuXi Biologics Announced Construction of a 69 million Integrated Manufacturing Center in Southwest China

WuXi Biologics commenced construction of a new 69 million integrated manufacturing centre for innovative biologics at Chengdu, Southwest China.

Features:

The innovative biologics manufacturing centre is to get constructed in 1.3 million square feet in Chengdu.

This facility is going to be the 12th drug substances manufacturing facility (MFG12) for WuXi Biologics.

The new facility will include drug development and commercial manufacturing facilities with an initial bioreactor capacity of 69 million.

WuXi Biologics will apply its extensive expertise as well as a well-established quality system that conforms to the highest international standards at this new integrated manufacturing centre.

The new construction will enable more global partners, create more jobs for local talents, stimulate high growth of the biologics industry in Chengdu as well as accelerate the biologics ecosystem in Southwest China.

Specifications:

NameWuXi Biologics
LocationChengdu, Southwest China
TypeNew Construction
Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024Equinix accelerated medical research...CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?